1
PUBLICATIONS
Peer reviewed articles
1. Ljung G, Norberg M, Hansson H, de la Torre, Egevad L, Busch C, Nilsson S:
Transrectal ultrasonically guided core biopsies in the assessment of local cure of
prostatic cancer after radical external beam radiotherapy. (Acta Oncol. 1995;
34:945-952)
2. Norberg M, Holmberg L, Busch C, Häggman M, Egevad L, Magnusson A:
Multiple transrectal ultrasound guided biopsies for the detection of prostate
cancer, determination of tumour volume, grade and seminal vesicle invasion.
(Eur Radiol. 1996; 6:56-61)
3. Ljung G, Egevad L, Norberg M, de la Torre M, Holmberg L, Busch C, Nilsson
S: Assessment of proliferation indicators in residual prostatic adenocarcinoma
cells after radical external beam radiotherapy. (The Prostate. 1996; 29:303-310)
4. Ljung G, Egevad L, Norberg M, Holmberg L, Nilsson S, Busch C: Expression
of p21 and mutant p53 gene products in residual prostatic tumor cells after
radical radiotherapy. (Prostate. 1997; 32(2):99-105)
5. Ranefall P, Egevad L, Nordin B, Busch C, Bengtsson E: A new method for
segmentation of colour images applied on immunohistochemically stained cells.
(Analytical Cellular Pathology. 1997; 15:145-156)
6. Bjelfman C, Söderström T, Brekkan E, Norlén B-J, Egevad L, Unge T,
Andersson S, Rane A: Differential gene expression of steroid 5a-reductase 2 in
in core needle biopsies from malignant and benign prostatic tissue. (J Clin
Endocrinol Metab. 1997; 82(7):2210-2214)
7. Norberg M, Egevad L, Holmberg L, Norlén B-J, Busch C: The sextant protocol
for ultrasound-guided core biopsies of the prostate underestimates the presence
of cancer. (Urology. 1997; 50:562-566)
8. Sundstrom C, Egevad L: More pathologists are needed in Sweden! Retirements
may cause a real crisis. (Lakartidningen. 1997; 94(26-27):2443)
9. Loughlin M, Carlbom I, Busch C, Douglas T, Egevad L, Frimmel H, Norberg
M, Sesterhenn I, Frogge J: Three-dimensional modeling of biopsy protocols for
localized prostate cancer. (Computerized Medical Imaging and Graphics. 1998;
22 (3):229-238)
10. Egevad L, Norberg M, Mattson S, Norlén B J, Busch C: Estimation of prostate
cancer volume by multiple core biopsies before radical prostatectomy. (Urology.
1998; 52(4):653-658)
11. Egevad L, Engström K, Busch C: A new method for handling radical
prostatectomies enabling fresh tissue harvesting, whole mount sections and
landmarks for alignment of sections. (Journal of Urologic Pathology. 1998;
9:17-28)
12. Busch C, Egevad L, Häggman M: Precancer of the prostate (Cancer Surveys
Volume 32: In Precancer: Biology, importance and possible prevention.
Precancer of the prostate. 1998, 149-179)
13. Egevad L, Frimmel H, Norberg M, Mattson S, Carlbom I, Bengtsson E, Busch
C: Three-dimensional computer reconstruction of prostate cancer from radical
prostatectomy specimens: Evaluation of the model by core biopsy simulation.
(Urology. 1999; 53:192-198)
14. Nilsson BO, Egevad L, Jin M, Ronquist G, Busch C: Distribution of
prostasomes in neoplastic epithelial prostate cells. (Prostate. 1999; 39:36-40)
15. Yang K, Lindblad P, Egevad L, Hemminki K: Novel somatic mutations in the
VHL gene in Swedish archived sporadic renal cell carcinomas. (Cancer
Letters.1999; 141(1-2):1-8)
16. Egevad L, Engström K, Mattson S, Wester K, Busch C: Heterogeneity of DNA
ploidy in prostate cancer. (Journal of Urologic Pathology. 1999; 10:23-37)
17. Egevad L, Frimmel H, Mattson S, Bengtsson E, Busch C: Biopsy protocol
stability in a three-dimensional model of prostate cancer: Changes in cancer
yield after adjustment of biopsy positions. (Urology.1999; 54(5):862-868)
18. Frimmel H, Egevad L, Bengtsson E, Busch C: Modeling prostate cancer
distributions. (Urology. 1999; 54(6):1028-1034)
19. Franck Lissbrant I, Stattin P, Wikström P, Damber J-E, Egevad L, Bergh A:
Tumor associated macrophages in human prostate cancer: relation to
clinicopathological variables and survival. (Int J Oncol.2000; 17(3):445-51)
20. Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman U-H, Egevad L,
Riboli E, Hallmans G, Kaaks R: Plasma insulin-like growth factor-I, insulin-like
growth factor-binding proteins, and prostate cancer risk: a prospective study. (J
Natl Cancer Inst. 2000; 92(23):1910-7)
21. Söderström T, Bjelfman C, Brekkan E, Ask B, Egevad L, Norlén B J , Rane A:
Messenger ribonucleic acid levels of steroid 5alpha-reductase 2 in human
prostate predict the enzyme activity. (Clin Endocrinol Metab. 2001; 86(2):855858)
22. Egevad L: Reproducibility of Gleason grading of prostate cancer can be
improved by the use of reference images. (Urology. 2001; 57 (2): 291-5)
2
23. Alaiya A, Roblick U, Egevad L, Carlsson A, Franzén B, Volz D, Huwendiek
S, Linder S, Auer G: Polypeptide expression in prostate hyperplasia and prostate
adenocarcinoma. (Analytical Cellular Pathology. 2001; 21(1):1-9)
24. Alaiya A, Oppermann M, Langridge J, Roblick U, Egevad L, Brändstedt S,
Hellström M, Linder S, Bergman T, Jörnvall H, Auer G: Identification of
proteins in human prostate tumor material by two-dimensional gel
electrophoresis and mass spectrometry. (Cell Mol. Life Sciences. 2001;
58(2):307-11)
25. Ma X, Yang K, Lindblad P, Egevad L, Hemminki K: VHL gene alteration in
renal cell carcinoma patients: Novel hotspot or founder mutation and linkage
disequilibrium. (Oncogene. 2001; 20(38):5393-400)
26. Egevad L, Norlén B J , Norberg M: The value of multiple core biopsies for
predicting the Gleason score of prostate cancer. (BJU Int. 2001; 88:716-721)
27. Andersson J, Ekman P, Egevad L, Hellström M: Relatively high risk of
treatment failure after prostatectomy: Tumour grade, histopathological stage and
the preoperative serum PSA level are key prognosticators. (Scand J Urol
Nephrol. 2001; 35 (6):453-458)
28. Finnström N, Bjelfman C, Söderström T, Smith G, Egevad L, Norlén B-J, Wolf
R, Rane A: Detection of cytochrome P450 mRNA transcripts in prostate
samples by RT-PCR. (Eur J Clin Invest. 2001; 31(10): 880-6)
29. Frimmel H, Egevad L, Busch C, Bengtsson E: Automatic registration and error
detection of multiple slices using landmarks. (Anal Cell Pathol. 2001;
23(3,4):159-165)
30. Hemminki K, Jiang Y, Ma X, Yang K, Egevad L, Lindblad P: Molecular
epidemiology of VHL gene mutations in renal cell carcinoma patients: Relation
to dietary and other factors. (Carcinogenesis. 2002; 23(5):809-815)
31. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P: Prognostic value of the
Gleason score in prostate cancer. (BJU Int. 2002; 89(6):538-42)
32. Wikström P, Franck Lissbrant I, Stattin P, Egevad L, Bergh A: Endoglin
(CD105) is expressed on immature blood vessels and is a marker for survival in
prostate cancer. (Prostate. 2002; 51(4):268-75)
33. Häggarth L, Ekman P, Egevad L: A new core-biopsy instrument with an
end-cut technique provides prostate biopsies with increased tissue yield. (BJU
Int, 2002; 90(1):51-5)
34. Sahlén G, Egevad L, Ahlander A, Norlén BJ, Ronquist G, Nilsson BO:
Ultrastructure of the secretion of prostasomes from benign and malignant
epithelial cells in the prostate. (The Prostate. 2002; 53(3):192-9)
3
35. Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P: Percent Gleason grade
4/5 as prognostic factor in prostate cancer diagnosed at transurethral resection. (J
Urol. 2002; 168(2):509-13)
36. Glaessgen A, Hamberg H, Pihl C-G, Sundelin B, Nilsson B, Egevad L:
Interobserver reproducibility of percent Gleason grade 4/5 in total prostatectomy
specimens. (J Urol. 2002; 168(5):2006-2010)
37. Egevad L: Cytology of the central zone of the prostate (Diagnostic
Cytopathology. 2003; 28(5):239-44)
38. Richardsen E, Ukkonen T, Bjørnsen T, Mortensen R, Egevad L, Busch C:
Overexpression of IGBFB2 is a marker for malignant transformation in prostate
cancer. (Virchows Arch. 2003; 442(4):329-35)
39. Shiao Y, Forsti A, Egevad L, Amderson LM, Lindblad P, Hemminki K: VHL
down-regulation and differential localization as mechanisms in tumorigenesis.
(Kidney Int. 2003; 64(5):1671-4.)
40. Glaessgen A, Hamberg H, Pihl C-G, Sundelin B, Nilsson B, Egevad L:
Interobserver reproducibility of percent Gleason grade 4/5 in prostate biopsies.
(J Urol. 2004; 171(2 Pt 1):664-7)
41. Key TJ, Allen N, Appleby P, Overvad K, Tjonneland A, Miller A, Boeing H,
Karalis D, Psaltopoulou T, Berrino F, Palli D, Panico S, Tumino R, Vineis P,
Bueno-De-Mesquita HB, Kiemeney L, Peeters PH, Martinez C, Dorronsoro M,
Gonzalez CA, Chirlaque MD, Quiros JR, Ardanaz E, Berglund G, Egevad L,
Hallmans G, Stattin P, Bingham S, Day N, Gann P, Kaaks R, Ferrari P, Riboli E:
Fruits and vegetables and prostate cancer: No association among 1,104 cases in
a prospective study of 130,544 men in the European Prospective Investigation
into Cancer and Nutrition (EPIC). (Int J Cancer. 2004; 109(1):119-24)
42. Lapointe J, Li C, Higgins JP, Van De Rijn M, Bair E, Montgomery K, Ferrari
M, Egevad L, Rayford W, Bergerheim U, Ekman P, DeMarzo AM, Tibshirani
R, Botstein D, Brown PO, Brooks JD, Pollack JR.: Gene expression profiling
identifies clinically relevant subtypes of prostate cancer. (Proc Natl Acad Sci U
S A. 2004; 101(3):811-6)
43.
See-Tong Pang, Xioalei Fang, Alexander Valdman, Gunnar Norstedt, Åke
Pousette, Lars Egevad* and Peter Ekman* (*Egevad and Ekman contributed
equally): Expression of Ezrin in Prostatic Intraepithelial Neoplasia. (Urology.
2004; 63(3):609-12)
44. Valdman A, Fang X, Pang S, Ekman P, Egevad L: Pim-1 expression in prostate
cancer and prostatic intraepithelial neoplasia. (The Prostate 2004; 60:367-71)
45. Glaessgen A, Hamberg H, Pihl C-G, Sundelin B, Nilsson B, Egevad L:
Interobserver reproducibility of modified Gleason score in radical prostatectomy
specimens. (Virchows Arch. 2004; 445(1):17-21)
4
46. Pavlenko M, Roos AK, Lundqvist A, Palmborg A, Miller AM, Ozenci V,
Bergman B, Egevad L, Hellstrom M, Kiessling R, Masucci G, Wersall P,
Nilsson S, Pisa P: A phase I trial of DNA vaccination with a plasmid expressing
prostate-specific antigen in patients with hormone-refractory prostate cancer. (Br
J Cancer. 2004; 91(4):688-94)
47. Lind AJ, Wikstrom P, Granfors T, Egevad L, Stattin P, Bergh A: Angiopoietin
2 expression is related to histological grade, vascular density, metastases, and
outcome in prostate cancer. (Prostate. 2005; 62(4):394-9)
48. Roos AK, Pavlenko M, Charo J, Egevad L, Pisa P.: Induction of PSA-specific
CTLs and anti-tumor immunity by a genetic prostate cancer vaccine. (Prostate.
2005; 62(3):217-23)
49. Egevad L, Allsbrook WC Jr, Epstein JI: Current practice of Gleason grading
among genitourinary pathologists. (Hum Pathol. 2005; 36(1):5-9)
50. Ozenci V, Miller AM, Palmborg A, Egevad L, Jaremko GA, Kalkner KM, Pisa
P.: Presence and specificity of tumor associated lymphocytes from ascites fluid
in prostate cancer. (Prostate. 2005; 65(1):20-6)
51. Lexander H, Franzen B, Hirschberg D, Becker S, Hellstrom M, Bergman T,
Jornvall H, Auer G, Egevad L.: Differential protein expression of normal
anatomical zones of the prostate. (Proteomics. 2005; 5(10):2570-6)
52. Srigley JR, Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA,
Mikuz G, Newling D, Nilsson S, Sakr W, Wheeler TM, Montironi R: Prognostic
and predictive factors in prostate cancer: historical perspectives and recent
international consensus initiatives. (Scand J Urol Nephrol Suppl. 2005 May;
(216):8-19)
53. Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G,
Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R.
Prognostic and predictive factors and reporting of prostate carcinoma in prostate
needle biopsy specimens. (Scand J Urol Nephrol Suppl. 2005 May;(216):20-33)
54. Epstein JI, Amin M, Boccon-Gibod L, Egevad L, Humphrey PA, Mikuz G,
Newling D, Nilsson S, Sakr W, Srigley JR, Wheeler TM, Montironi R:
Prognostic factors and reporting of prostate carcinoma in radical prostatectomy
and pelvic lymphadenectomy specimens. (Scand J Urol Nephrol Suppl. 2005
May;(216):34-63)
55. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad L; and the ISUP Grading
Committee: The 2005 International Society of Urological Pathology (ISUP)
Consensus Conference on Gleason Grading of Prostatic Carcinoma. (Am J Surg
Pathol. 2005; 29(9):1228-1242)
56. Josefsson A, Wikström P, Egevad L, Granfors T, Karlberg L, Stattin P, Bergh
A: Non-aggressive Gleason score 6 prostate tumors can be identified by tumor
size and vascular density. (Eur Urol. 2005; 48(4):577-83)
5
6
57. Valdman A, Fang X, Pang S, Nilsson B, Ekman P, Egevad L: Ezrin expression
in prostate cancer and benign prostatic tissue. (Eur Urol. 2005; 48(5):852-7)
58. Häggarth L, Busch C , Norberg M, Norlén B J, Egevad L: Prediction of large
prostate cancer volume by multiple core biopsies. (Scand J Urol Nephrol. 2005;
39(5):380-386)
59. Häggarth L, Auer G, Busch C , Norberg M, Häggman M, Egevad L: The
significance of tumor heterogeneity for prediction of DNA ploidy of prostate
cancer. (Scand J Urol Nephrol. 2005; 39(5):387-92)
60. Lexander H, Franzén B, Hellström B, Auer G, Jörnvall H, Egevad L: Proteomic
analysis of protein expression in prostate cancer. (Anal Quant Cytol Histol.
2005; 27(5):263-72)
61. Fang X, Liu Z, Fan Y, Zheng C, Nilson S, Egevad L, Ekman P, Xu D: Switch to
full-length of XAF1 mRNA expression in prostate cancer cells by the DNA
methylation inhibitor. (Int J Cancer. 2006; 118(10):2485-9)
62. Egevad L, Allsbrook WC Jr, Epstein JI: Current practice of diagnosis and
reporting of prostatatic intraepithelial neoplasia and glandular atypia among
genitourinary pathologists. (Mod Pathol. 2006; 19(2):180-5)
63. Epstein JI, Allsbrook WC Jr, Amin MB, Egevad L: Update on the Gleason
Grading System for prostate cancer: Results of an International Consensus
Conference of Urologic Pathologists. (Adv Anat Pathol. 2006; 13(1):57-59)
64. Valdman A, Jonmarker S, Ekman P, Egevad L: Cytological features of prostatic
intraepithelial neoplasia. (Diagn Cytopathol. 2006; 34(5):317-22)
65. Egevad L, Allsbrook WC Jr, Epstein JI: Current practice of diagnosis and
reporting of prostate cancer on needle biopsy among genitourinary pathologists.
(Hum Pathol. 2006; 37(3):292-7)
66. Lexander H, Hellman U, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall
H, Egevad L: Evaluation of two sample preparation methods for prostate
proteome analysis. (Proteomics. 2006; 6(13):3918-25)
67. Culp WD, Neal R, Massey R, Egevad L, Pisa P, Garland D: Proteomic analysis
of tumor establishment and growth in the B16-F10 mouse melanoma model. (J
Proteome Res. 2006; 5(6):1332-43)
68. Lexander H, Palmberg C, Hellman U, Auer G, Hellström M, Franzén B, Jörnvall
H, Egevad L: Correlation of protein expression, Gleason score and DNA ploidy
in prostate cancer. (Proteomics. 2006; 6(15):4370-80)
69. Jonmarker S, Valdman A, Lindberg A, Hellström M, Egevad L: Tissueshrinkage after fixation with formalin injection of prostatectomy specimens.
(Virchows Archiv. 2006; 449(3): 297-301)
7
70. De Marzo AM, Platz EA, Epstein JI, Ali T, Billis A, Chan TY, Cheng L, Datta
M, Egevad L, Ertoy-Baydar D, Farree X, Fine SW, Iczkowski KA, Ittmann M,
Knudsen BS, Loda M, Lopez-Beltran A, Magi-Galluzzi C, Mikuz G, Montironi
R, Pikarsky E, Pizov G, Rubin MA, Samaratunga H, Sebo T, Sesterhenn IA,
Shah RB, Signoretti S, Simko J, Thomas G, Troncoso P, Tsuzuki TT, van
Leenders GJ, Yang XJ, Zhou M, Figg WD, Hoque A, Lucia MS: A working
group classification of focal prostate atrophy lesions. (Am J Surg Pathol.
2006;30(10):1281-91)
71. Eriksson F, Culp WD, Massey R, Egevad L, Garland D, Persson MA, Pisa P:
Tumor specific phage particles promote tumor regression in a mouse melanoma
model. (Cancer Immunol Immunother. 2007 May;56(5):677-87)
72. Hellström M, Lexander H, Franzén B, Egevad L: Proteomics in prostate cancer
research. (Anal Quant Cytol Histol. 2007 Feb;29(1):32-40)
73. Glaessgen A, Busch C, Norberg M, Häggman M, Nilsson B, Egevad L:
Prediction of percent Gleason Grade 4/5 by multiple core biopsies. (Scan J Urol
Nephrol 2006;40(6):465-71)
74. Miller AM, Egevad L, Lundberg K, Özenci V, Banham AH, Hellström M, Pisa
P: CD4+CD25high regulatory T cells are enriched in the peripheral blood and
tumor tissue of patients with prostate cancer (J Immunol. 2006 Nov
15;177(10):7398-405)
75. Helpap B, Egevad L: The significance of modified Gleason grading of prostatic
carcinoma in biopsy and radical prostatectomy specimens (Virchows Arch. 2006
Dec;449(6):622-7)
76. Helpap B, Egevad L:. Die Wertigkeit des 2005 modifizierten Gleason Grading
in der urologischen Diagnostik von Prostatakarzinomen. (Urologe A. 2007
Jan;46(1):59-62)
77. Rydén L, Egevad L, Ekman P, Hellström M: Prevalence of prostate cancer at
different levels of serum prostate-specific antigen (PSA) and different free: total
PSA ratios in a consecutive series of men referred for prostate biopsies. (Scand J
Urol Nephrol. 2007;41(4):302-7)
78. Egevad L, Ehrnström R, Håkansson U, Grabe M: Primary seminal vesicle
carcinoma diagnosed at transurethral resection of the prostate. (Urology. 2007
Apr;69(4):778.e11-3.)
79. Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, Egevad L,
Gann PH, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF,
Tjønneland A, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S,
Khaw KT, Tumino R, Sieri S, Vineis P, Palli D, Quirós JR, Ardanaz E,
Chirlaque MD, Larrañaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Bikou
C, Trichopoulos D, Stattin P, Jenab M, Ferrari P, Slimani N, Riboli E, Kaaks R.
Serum androgens and prostate cancer among 643 cases and 643 controls in the
European Prospective Investigation into Cancer and Nutrition. (Int J Cancer.
2007 Sep 15;121(6):1331-8)
80. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L,
Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjønneland A,
Grønbaek H, Overvad K, Kiemeney L, Bueno-de-Mesquita HB, Bingham S,
Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, Palli D, Quirós JR,
Ardanaz E, Navarro C, Larrañaga N, Gonzalez C, Sanchez MJ, Trichopoulou A,
Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R: Serum
insulin-like growth factor (IGF)-I and IGF-binding protein-3 concentrations and
prostate cancer risk: results from the European Prospective Investigation into
Cancer and Nutrition. (Cancer Epidemiol Biomarkers Prev. 2007
Jun;16(6):1121-7)
81. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L,
Tjønneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H,
Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Palli D, Vineis P,
Tumino R, Berrino F, Kiemeney L, Bueno-de-Mesquita HB, Quirós JR,
González CA, Martinez C, Larrañaga N, Chirlaque MD, Ardanaz E, Stattin P,
Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E:
Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in
the European Prospective Investigation into Cancer and Nutrition study. (Am J
Clin Nutr. 2007 Sep;86(3):672-81.)
82. Magnus Hellström, Sara Jonmarker, Janne Lehtiö, Gert Auer and Lars Egevad
Proteomics in clinical prostate research (Proteomics Clin Appl, 2007;1:1058-65)
83. Algaba F, Mikuz G, Boccon-Gibod L, Trias I, Arce Y, Montironi R, Egevad L,
Scarpelli M, Lopez-Beltran A. Pseudoneoplastic lesions of the testis and
paratesticular structures.(Virchows Arch. 2007 Dec;451(6):987-97)
84. Braeckman J, Autier P, Garbar C, Marichal MP, Soviany C, Nir R, Nir D,
Michielsen D, Bleiberg H, Egevad L, Emberton M: Computer-aided
ultrasonography (HistoScanning): a novel technology for locating and
characterizing prostate cancer. (BJU Int. 2008 Feb;101(3):293-8)
85. Johansson M, Appleby PN, Allen NE, Travis RC, Roddam AW, Egevad L,
Jenab M, Rinaldi S, Kiemeney LA, Bueno-de-Mesquita HB, Vollset SE, Ueland
PM, Sánchez MJ, Quirós JR, González CA, Larrañaga N, Chirlaque MD,
Ardanaz E, Sieri S, Palli D, Vineis P, Tumino R, Linseisen J, Kaaks R, Boeing
H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Khaw KT,
Bingham S, Hallmans G, Riboli E, Stattin P, Key TJ: Circulating concentrations
of folate and vitamin B12 in relation to prostate cancer risk: results from the
European prospective investigation into cancer and nutrition study. (Cancer
Epidemiol Biomarkers Prev. 2008 Feb;17(2):279-85.)
86. Helpap B, Egevad L: Correlation of Modified Gleason Grading With pT Stage
of Prostatic Carcinoma After Radical Prostectomy (Anal Quant Cytol Histol.
2008 Feb;30(1):1-7)
8
87. S Rohrmann, J Linseisen, TJ Key, MK Jensen, K Overvad, N Føns Johnsen,
A Tjønneland, R Kaaks, M Bergmann, C Weikert, A Naska, A Trichopoulou, D
Trichopoulos, V Pala, HB Bueno-de-Mesquita, A Vrieling, CA González, N
Larrañaga, C Navarro, G Hallmans, P Stattin, J Manjer, E Wirfält, L Egevad, P
Ferrari, M Jenab, E Riboli: Alcohol consumption and the risk of prostate cancer
in the European Prospective Investigation into Cancer and Nutrition (EPIC)
(Cancer Epidemiol Biomarkers Prev., 2008; 17(5), 1282-7)
88. Helpap B, Egevad L: Correlation of modified Gleason grading of prostate
carcinoma with age, serum prostate specific antigen and tumor extent in needle
biopsy specimens (Anal Quant Cytol Histol. 2008 Jun;30(3):133-8)
89. Egevad L: Recent Trends in Gleason Grading of Prostate Cancer (I): Pattern
Interpretation (Anal Quant Cytol Histol, 2008 Aug;30(4):190-8)
90. Egevad L: Recent Trends in Gleason Grading of Prostate Cancer (II):
Prognosis, Reproducibility and Reporting (Anal Quant Cytol Histol, 2008
Oct;30(5):254-60)
91. Anca Reschner, Helena Harlin, Brett Laven, Fredrik Eriksson, Pavel Pisa, Lars
Egevad Expression of immunomodulating genes in prostate cancer and benign
prostatic tissue (Anal Quant Cytol Histol, 2009 Apr;31(2):74-82)
92. S Jonmarker, A Glaessgen, WD Culp, P Pisa, R Lewensohn, P Ekman, A
Valdman, L Egevad: Expression of PDX-1 in prostatic carcinoma, PIN and
benign prostatic tissue (APMIS. 2008 Jun;116(6):491-8)
93. L Egevad, F Algaba, DM Berney, L Boccon-Gibod, D Griffiths, A LopezBeltran, G Mikuz, M Varma, R Montironi: Handling and Reporting of Radical
Prostatectomy Specimens in Europe; A Web-Based Survey by The European
Network of Uropathology (ENUP) (Histopathology. 2008 Sep;53(3):333-9)
94. Egevad L, Castellanos E, Hellström M, Valdman A: Atypical stromal
hyperplasia of the prostate (Scand J Urol Nephrol. 2008;42(5):484-7)
95. Axel Glaessgen, Sara Jonmarker, Anna Lindberg, Bo Nilsson, Rolf Lewensohn,
Peter Ekman, Alexander Valdman, Lars Egevad: Heat shock proteins 27, 60
and 70 as prognostic markers of prostate cancer (APMIS, 2008
Oct;116(10):888-95)
96. AJ Evans, PC Henry, T Van der Kwast, D Tkachuk, K Watson, G Lockwood,
NE Fleshner, C Cheung, E Belanger, M Amin, L Bocon-Gibod, DG Bostwick, L
Egevad, JI Epstein, D Grignon, E Jones, R Montironi, M Moussa, JM Sweet, K
Trypkov, T Wheeler, JR Srigley: Interobserver variability between expert
urological pathologists for extra-prostatic extension and surgical margin status
in radical prostatectomy specimens. (Am J Surg Pathol, 2008 Oct;32(10):150312)
97. M Latour, MB Amin, A Billis, L Egevad, D Grignon, PA Humphrey, VE
Reuter, WA Sakr, JR Srigley, TM Wheeler, XJ Yang, JI Epstein: Grading of
9
Invasive Cribriform Carcinoma on Prostate Needle Biopsy: An Interobserver
Study among Experts in Genitourinary Pathology (Am J Surg Pathol, 2008
Oct;32(10):1532-9)
98. L Egevad, F Algaba, DM Berney, L Boccon-Gibod, D Griffiths, A LopezBeltran, G Mikuz, M Varma, R Montironi; The ENUP Members: The European
Network of Uropathology: A Novel Mechanism for Communication between
Pathologists (Anal Quant Cytol Histol, 2009 Apr;31(2):90-5)
99. Rubio CA, Orrego A, Höög A, Porwitz A, Petersson F, Elmberger G, Glaessgen
A, Eriksson E, Kanter L, Jaremko G, Egevad L, Laforga J, Liljefors M, Löfdahl
B, Norman P, Larsson O, Wanat R, Wejde J, Zickert P, Björk J, Caini S, Palli D,
Nesi G: Quantitative assessment of the subepithelial collagen band does not
increase the accuracy of diagnosis of collagenous colitis (Am J Clin Pathol.
2008 Sep;130(3):375-81.)
100.
Rosenblatt R, Valdman A, Cheng L, Lopez-Beltran A, Montironi R,
Ekman P, Egevad L: Endothelin-1 expression in prostate cancer and high-grade
PIN (Anal Quant Cytol Histol. 2009 Jun;31(3):137-42.)
101.
Lopez-Beltran A, Kirkali Z, Cheng L, Egevad L, Regueiro JC, Montironi
R: Targeted therapies and biological modifiers in urologic tumors, pathobiology
and clinical implications. (Semin Diagn Pathol, 2008 Nov;25(4):232-44)
102.
Egevad L, Håkansson U, Grabe M, Ehrnström R: Urachal signet-cell
adenocarcinoma (Scand J Urol Nephrol. 2009;43(1):88-91)
103.
Rosenblatt R, Jonmarker S, Lewensohn R, Egevad L, Sherif A, Kälkner
KM, Nilsson S, Valdman A, Ullén A: Current status of prognostic
immunohistochemical markers for urothelial bladder cancer. (Tumour Biol.
2008;29(5):311-22)
104.
Helpap B, Egevad L: Zur klinischen Insignifikanz des Prostatakarzinom.
Gibt es morphologische Hinweise? (Urologe A. 2009 Feb;48(2):170-4)
105.
R Suzuki, NE Allen, TJ Key, PN Appleby, A Tjønneland, N Føns
Johnsen, MK Jensen, K Overvad, H Boeing, T Pischon, R Kaaks, S Rohrmann,
A Trichopoulou, M Gesthimani, D Trichopoulos, HB Bueno-de-Mesquita, F van
Duijnhoven, C Sacerdote, S Grioni, D Palli, R Tumino, E Ardanaz, J Ramón
Quirós, N Larrañaga, MJ Sánchez, MJ Tormo, P Jakszyn, I Johansson, P Stattin,
G Berglund, J Manjer, S Bingham, KT Khaw, L Egevad, P Ferrari, M Jenab, E
Riboli: A prospective analysis of the association between dietary fiber intake
and prostate cancer risk in EPIC (Int J Cancer. 2009 Jan 1;124(1):245-9)
106.
Valdman A, Häggarth L, Cheng L, Lopez-Beltran A, Montironi R, Ekman
P, Egevad L: Expression of redox pathway enzymes in human prostatic tissue
(Anal Quant Cytol Histol, 2009, 31(6):367-)
107.
Sui Chu Chung, Peter Hammarsten, Andreas Josefsson , Pär Stattin,
Torwald Granfors, Lars Egevad, Anders Bergh, Christopher J. Fowler: A high
10
cannabinoid CB(1) receptor immunoreactivity is associated with disease
severity and outcome in prostate cancer. (Eur J Cancer. 2009 Jan;45(1):174-82)
108.
Helpap B, Egevad L: Modified Gleason Grading. An Updated Review
(Histology and Histopathology, 2009 May;24(5):661-6.)
109.
Compérat E, Egevad L, Camparo P, Roupret M, Vaessen C, Valdman A,
Jonmarker S, Richard F, Capron F, Cussenot O, Charlotte F: Clinical
significance of intratumoral CD8+ regulatory T Treg cells in prostate carcinoma
(Anal Quant Cytol Histol, 2010;32(1):39–44)
110.
Føns Johnsen N, Tjønneland A, Thomsen BLR, Christensen J, Loft S,
Friedenreich C, Key T, Allen N, Lahmann PH, Overvad K, Kaaks R, Rohrmann
S, Boing H, Misirli G, Trichopoulou A, Zilis D, Tumino R, Pala V, Bueno-deMesquita HB, Kiemeney LA, Gonzales C, María J, Manjer J, Wirfält E, Khaw
KT, Wareham N, Boffetta P, Egevad L, Rinaldi S, Riboli E: Physical activity
and risk of prostate cancer in the European Prospective - Investigation into
Cancer and Nutrition (EPIC) cohort. (Int J Cancer. 2009 Feb 3. [Epub ahead of
print])
111.
M Augsten, C Sundquist, E Olsson, C Stolz, P Tsagozis, T Levchenko, MJ
Frederick, Å Borg, L Egevad, P Micke, A Östman: CXCL14 produced by
cancer- associated fibroblasts is a multi-modal stimulator of prostate tumor
growth (Proc Natl Acad Sci U S A. 2009 Mar 3;106(9):3414-9)
112.
Egevad L, Montorsi F, Montironi R: Donald F. Gleason (1920-2008).
(Eur Urol, 2009 Feb 5. [Epub ahead of print])
113.
FL Büchner, HB Bueno-de-Mesquita, MM Ros, E Kampman, L Egevad,
K Overvad, O Raaschou-Nielsen, A Tjonneland, N Roswall, F Clavel-Chapelon,
J Chang-Claude, R Kaaks, H Boeing, S Weikert, A Trichopoulou, F Berrino, P.
Vineis, R Tumino, S Panico, A Vrieling, PHM Peeters, E Lund, IT Gram, C
Martinez, CA Gonzalez, G Berglund, G Hallmans, B Ljungberg, TJ Key, AW
Roddam, S Bingham, N Slimani, L.A.L.M Kiemeney, E Riboli: Consumption of
vegetables and fruit and the risk of bladder cancer in the European Prospective
Investigation into Cancer and Nutrition (Int J Cancer. 2009 Dec 1;125(11):264351)
114.
John R. Srigley, Peter A. Humphrey, Mahul B. Amin, Sam S. Chang, Lars
Egevad, Jonathan I. Epstein, David J. Grignon, James M. McKiernan, Rodolfo
Montironi, Andrew A. Renshaw, Victor E. Reuter, Thomas M. Wheeler:
Protocol for the Examination of Specimens From Patients With Carcinoma of
the Prostate Gland (Archives of Pathology and Laboratory Medicine, 2009
Oct;133(10):1568-76)
115.
Jonmarker Jaraj S, Camparo P, Boyle H, Germain F, Nilsson B, Petersson
F, Egevad L. Intra- and interobserver reproducibility of interpretation of
immunohistochemical stains of prostate cancer. (Virchows Arch. 2009 Sep 18)
11
116.
Antonio Lopez-Beltran, Rodolfo Montironi, Lars Egevad, Maria T
Caballero-Vargas, Marina Scarpelli, Ziya Kirkali, Liang Cheng: Genetic profiles
in renal tumors. (Int J Urol. 2010 Jan;17(1):6-19. Epub 2009 Oct 13)
117.
Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikström P,
Egevad L, Granfors T, Stattin P, Bergh A. Low levels of phosphorylated
epidermal growth factor receptor in nonmalignant and malignant prostate tissue
predict favorable outcome in prostate cancer patients. Clin Cancer Res. 2010
Feb 15;16(4):1245-55. Epub 2010 Feb 9
118.
A-E Carsin, F J Drummond, A Black, P.J van Leeuwen, L Sharp, LJ
Murray, D Connolly, L Egevad, M Boniol, P Autier, H Comber, A Gavin:
Impact of PSA testing and prostatic biopsy on cancer incidence and mortality:
comparative study between the Republic of Ireland and Northern Ireland.
(Cancer Causes Control. 2010 Jun 1. [Epub ahead of print])
119.
Alexander Valdman, Sara Jonmarker Jaraj, Eva Compérat, Fréderic
Charlotte, Morgan Roupret, Pavel Pisa, Lars Egevad: Distribution of Foxp3,
CD4 and CD8 positive lymphocytic cells in benign and malignant prostate tissue
(Apmis, 2010 May;118(5):360-5)
120.
Sara Jonmarker Jaraj, Lars Egevad: Formalin Fixation and
Immunoreactivity in Prostate Cancer and Benign Prostatic Tissue (Apmis, 2010
May;118(5):383-8)
121.
Benny Holmström,, Erik Holmberg, Lars Egevad, Jan Adolfsson, JanErik Johansson, Jonas Hugosson, and Pär Stattin on behalf of the National
Prostate Cancer Register (NPCR) of Sweden: Primary vs. Deferred Radical
Prostatectomy in The National Prostate Cancer Register (NPCR) of Sweden
(accepted, J Urol)
122.
A Lopez-Beltran, F Algaba, DM Berney, L Boccon-Gibod, P Camparo, D
Griffiths, , G Mikuz, R Montironi, M Varma, L Egevad; Handling and
Reporting of Transurethral Resection Specimens of the Bladder in Europe: A
Web-Based Survey by the European Network of Uropathology (ENUP)
(Histopathology, 2011 Mar;58(4):579-585)
123.
Gouas DA, Shi H, Hautefeuille AH, Ortiz-Cuaran SL, Legros PC,
Szymanska KJ, Galy O, Egevad LA, Abedi-Ardekani B, Wiman KG, Hantz O,
Caron de Fromentel C, Chemin IA, Hainaut PL: Effects of the TP53 p.R249S
mutant on proliferation and clonogenic properties in human hepatocellular
carcinoma cell lines: interaction with hepatitis B virus X protein.
(Carcinogenesis. 2010 Aug;31(8):1475-82. Epub 2010 Jun 10)
124.
F.L. Büchner, H.B. Bueno-de-Mesquita, M.M. Ros, E. Kampman, L.
Egevad, K Overvad, A Tjønneland, N Roswall, F Clavel-Chapelon, M-C
Boutron-Ruault, M Touillaud, R Kaaks J Chang-Claude, H Boeing, S Weikert,
A Trichopoulou , A Naska , V Benetou , D Palli, S Sieri, P. Vineis, R Tumino, S
Panico, FJB van Duijnhoven, PHM Peeters, CH van Gils, E Lund, I.T. Gram,
M-J Sánchez , P Jakszyn, N Larrañaga, E Ardanaz, C Navarro, L Rodríguez, J
12
Manjer, R Ehrnström, G Hallmans, B Ljungberg, TJ Key , NE Allen , K-T
Khaw, N Wareham, N Slimani, M Jenab, P Boffetta, L.A.L.M Kiemeney, E
Riboli: Variety in vegetable and fruit consumption and risk of bladder cancer in
the European Prospective Investigation into Cancer and Nutrition (Int J Cancer,
2011 15;128(12):2971-9)
125.
Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson
J; National Prostate Cancer Register (NPCR) of Sweden. Outcomes in localized
prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J
Natl Cancer Inst. 2010 Jul 7;102(13):950-8. Epub 2010 Jun 18.
126.
Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J,
Stattin P, Egevad L, Granfors T, Wikström P, Bergh A. Mast Cells Are Novel
Independent Prognostic Markers in Prostate Cancer and Represent a Target for
Therapy. Am J Pathol. 2010 Aug;177(2):1031-41. Epub 2010 Jul 8.
127.
Lars Egevad , Alexander Valdman , N Peter Wiklund , Pascal Sève ,
Charles Dumontet: Beta Tubulin III Expression in Prostate Cancer (Scan J Urol
Nephrol, 2010 Dec;44(6):371-7)
128.
Lars Egevad, John R Srigley and Brett Delahunt: International Society of
Urological Pathology (ISUP) consensus conference on handling and staging of
radical prostatectomy specimens: rationale and organization (Mod Pathol 2011;
24: 1-5)
129.
Hemamali Samaratunga, Rodolfo Montironi, Lawrence True, Jonathan
Epstein, Peter Humphrey, Theo van der Kwast, Thomas Wheeler, Brett
Delahunt, John Srigley, Lars Egevad, The ISUP prostate consensus
group:International Society of Urological Pathologists (ISUP) Consensus
Conference on Handling and Staging of Radical Prostatectomy Specimens.
Working Group 1: Handling of The Specimen (Mod Pathol 2011; 24: 6-15)
130.
Theo van der Kwast, Mahul Amin, Athanase Billis, Jonathan Epstein,
David Griffiths, Peter Humphrey, Rodolfo Montironi, Thomas Wheeler, John
Srigley, Lars Egevad, Brett Delahunt, The ISUP prostate consensus
group:International Society of Urological Pathologists (ISUP) Consensus
Conference on Handling and Staging of Radical Prostatectomy Specimens.
Working Group 2: pT2 Tumors and Tumor Volume (Mod Pathol 2011; 24: 1625)
131.
Cristina Magi-Galuzzi, Andrew Evans, Jonathan Epstein, Theo van der
Kwast, Rodolfo Montironi, Thomas Wheeler, Brett Delahunt, John Srigley, Lars
Egevad, Peter Humphrey, The ISUP prostate consensus group: International
Society of Urological Pathologists (ISUP) Consensus Conference on Handling
and Staging of Radical Prostatectomy Specimens. Working Group 3:
Extraprostatic Extension and Microvessel Invasion (Mod Pathol 2011; 24: 2638)
132.
Daniel Berney, Thomas Wheeler, David Grignon, Jonathan Epstein, David
Griffiths, Peter Humphrey, Theo van der Kwast, Rodolfo Montironi, Brett
13
Delahunt, Lars Egevad, John Srigley, The ISUP prostate consensus group:
International Society of Urological Pathologists (ISUP) Consensus Conference
on Handling and Staging of Radical Prostatectomy Specimens. Working Group
4: Seminal Vesicles and Lymph Nodes (Mod Pathol 2011; 24: 39-47)
133.
Puay Hoon Tan, Liang Cheng, Peter Humphrey, Theo van der Kwast,
Rodolfo Montironi, Thomas Wheeler, Brett Delahunt, John Srigley, Lars
Egevad, Jonathan Epstein, The ISUP prostate consensus group: International
Society of Urological Pathologists (ISUP) Consensus Conference on Handling
and Staging of Radical Prostatectomy Specimens. Working Group 5: Surgical
Margins (Mod Pathol 2011; 24: 48-57)
134.
Lina Thors, Anders Bergh, Emma Persson, Peter Hammarsten, Pär Stattin,
Lars Egevad, Torvald Granfors, Christopher J. Fowler: Fatty acid amide
hydrolase expression in prostate cancer: association with disease severity and
outcome, cannabinoid receptor-1 expression and regulation by interleukin-4
(PLoS ONE, 2010 Aug 19;5(8))
135.
Sara Jonmarker Jaraj, Martin Augsten, Lars Häggarth, Kenneth Wester,
Fredrik Pontén, Arne Östman, Lars Egevad: GAD1 is A Novel Prostate–
Specific Tissue Biomarker (Scand J Urol Nephrol, 2011 Feb;45(1):39-45. Epub
2010 Nov 22.)
136.
Lars Häggarth, Christina Hägglöf, Sara Jonmarker Jaraj, Kenneth Wester,
Fredrik Pontén, Arne Östman, Lars Egevad : Diagnostic Biomarkers of Prostate
Cancer (Scand J Urol Nephrol, 2011 Feb;45(1):60-7. Epub 2010 Nov 1)
137.
Carlos A Gonzalez , Leila - Lujan Barroso, Martine M Ros, H Bas Buenode-Mesquita, Nina Roswall, Anne M Tjonneland, Frederike L Buchner, Lars
Egevad, Kim Overvad, Ole Raaschou-Nielsen, Francoise Clavel-Chapelon,
Marie-Christine Boutron-Ruault, Marina S Touillaud, J Chang-Claude, Naomi E
Allen, Lambertus A Kiemeney, Timothy J Key, Rudolf Kaaks, Heiner Boeing,
Steffen Weikert, Antonia Trichopoulou, E Oikonomou, Dimosthenis Zylis,
Domenico Palli, Franco Berrino, Paolo P Vineis, Rosario Tumino, Amalia
Mattiello, Alina Vrieling, Petra H.M. Peeters, Christine L Parr, Inger Torhild
Gram, Guri Skeie, Maria-Jose Sanchez, Nerea Larrañaga, Eva Ardanaz, Carmen
Navarro, Laudina Rodriguez, David Ulmert, Roy Ehrnstrom, Göran Hallmans,
Borje Ljungberg, Andrew Wilfred Roddam, Sheila A Bingham, Kay-Tee Khaw,
Nadia Slimani, Paolo A Boffetta, Mazda Jenab, Traci Mouw, Dominique S
Michaud, Elio Riboli: Red meat, dietary nitrosamines and heme iron and risk of
bladder cancer in the European Prospective Investigation into Cancer and
Nutrition (EPIC) (Cancer Epidemiology, Biomarkers & Prevention)
138.
Marcus Thomasson , Baofeng Wang, Peter Hammarsten, Anna Dahlman,
Jenny Liao Persson, Andreas Josefsson, Pär Stattin, Torvald Granfors, Lars
Egevad, Roger Henriksson, Anders Bergh, and Håkan Hedman LRIG and the
liar paradox in prostate cancer: A study of the expression and clinical
significance of LRIG1 in prostate cancer (Int J Cancer. 2011 Jun
15;128(12):2843-52)
14
139.
Jakszyn P, González CA, Luján-Barroso L, Ros MM, Bueno-deMesquita HB, Roswall N, Tjønneland AM, Büchner FL, Egevad L, Overvad K,
Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud MS,
Chang-Claude J, Allen NE, Kiemeney LA, Key TJ, Kaaks R, Boeing H, Weikert
S, Trichopoulou A, Oikonomou E, Zylis D, Palli D, Berrino F, Vineis P, Tumino
R, Mattiello A, Peeters PH, Parr CL, Gram IT, Skeie G, Sánchez MJ, Larrañaga
N, Ardanaz E, Navarro C, Rodríguez L, Ulmert D, Ehrnström R, Hallmans G,
Ljungberg B, Roddam AW, Bingham SA, Khaw KT, Slimani N, Boffetta PA,
Jenab M, Mouw T, Michaud DS, Riboli E. Red meat, dietary nitrosamines, and
heme iron and risk of bladder cancer in the European Prospective Investigation
into Cancer and Nutrition (EPIC). Cancer Epidemiol Biomarkers Prev. 2011
Mar;20(3):555-9. Epub 2011 Jan 14.
140.
Chargari C, Comperat E, Magné N, Védrine L, Houlgatte A, Egevad L,
Camparo P. Prostate needle biopsy examination by means of virtual microscopy.
Pathol Res Pract. 2011 May 13. [Epub ahead of print]
141.
Ros MM, Bas Bueno-de-Mesquita HB, Büchner FL, Aben KK, Kampman
E, Egevad L, Overvad K, Tjønneland A, Roswall N, Clavel-Chapelon F, Kaaks
R, Chang-Claude J, Boeing H, Weikert S, Trichopoulou A, Orfanos P,
Stasinopulou G, Saieva C, Krogh V, Vineis P, Tumino R, Mattiello A, Peeters
PH, van Duijnhoven FJ, Lund E, Gram IT, Chirlaque MD, Barricarte A,
Rodríguez L, Molina E, Gonzalez C, Dorronsoro M, Manjer J, Ehrnström R,
Ljungberg B, Allen NE, Roddam AW, Khaw KT, Wareham N, Boffetta P,
Slimani N, Michaud DS, Kiemeney LA, Riboli E. Fluid intake and the risk of
urothelial cell carcinomas in the European Prospective Investigation into Cancer
and Nutrition (EPIC). Int J Cancer. 2011 Jun 1;128(11):2695-708. doi:
10.1002/ijc.25592. Epub 2010 Oct 8.
142.
Berney DM, Montironi R, Egevad L. Pathology in prostate research:
optimizing the pathological data. Acta Oncol. 2011 Jun;50 Suppl 1:49-52.
143.
Berney DM, Montironi R, Egevad L. Pathology in prostate research:
optimizing tissue quality. Acta Oncol. 2011 Jun;50 Suppl 1:53-5.
144.
Montironi R, Egevad L, Bjartell A, Berney DM. Role of histopathology
and molecular markers in the active surveillance of prostate cancer. Acta Oncol.
2011 Jun;50 Suppl 1:56-60.
145.
Bjartell A, Montironi R, Berney DM, Egevad L. Tumour markers in
prostate cancer II: diagnostic and prognostic cellular biomarkers. Acta Oncol.
2011 Jun;50 Suppl 1:76-84.
146.
Chargari C, Comperat E, Magné N, Védrine L, Houlgatte A, Egevad L,
Camparo P. Prostate needle biopsy examination by means of virtual microscopy.
Pathol Res Pract. 2011 Jun 15;207(6):366-9.
147.
Büchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L,
Overvad K, Tjønneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC,
Touillaud M, Kaaks R, Chang-Claude J, Boeing H, Weikert S, Trichopoulou A,
15
Naska A, Benetou V, Palli D, Sieri S, Vineis P, Tumino R, Panico S, van
Duijnhoven FJ, Peeters PH, van Gils CH, Lund E, Gram IT, Sánchez MJ,
Jakszyn P, Larrañaga N, Ardanaz E, Navarro C, Rodríguez L, Manjer J,
Ehrnström R, Hallmans G, Ljungberg B, Key TJ, Allen NE, Khaw KT,
Wareham N, Slimani N, Jenab M, Boffetta P, Kiemeney LA, Riboli E. Variety
in vegetable and fruit consumption and risk of bladder cancer in the European
Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2011 Jun
15;128(12):2971-9.
148.
Thomasson M, Wang B, Hammarsten P, Dahlman A, Persson JL,
Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, Bergh A, Hedman
H. LRIG1 and the liar paradox in prostate cancer: a study of the expression and
clinical significance of LRIG1 in prostate cancer. Int J Cancer. 2011 Jun
15;128(12):2843-52.
149.
Egevad L, Srigley JR, Delahunt B. International society of urological
pathology consensus conference on handling and staging of radical
prostatectomy specimens. Adv Anat Pathol. 2011 Jul;18(4):301-5.
150.
Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Compérat E, Evans
AJ, Grobholz R, Kristiansen G, Langner C, Lockwood G, Lopez-Beltran A,
Montironi R, Oliveira P, Schwenkglenks M, Vainer B, Varma M, Verger V,
Camparo P. Interactive digital slides with heat maps: a novel method to improve
the reproducibility of Gleason grading. Virchows Arch. 2011 Aug;459(2):17582. Epub 2011 Jun 23.
151.
Kench JG, Clouston DR, Delprado W, Eade T, Ellis D, Horvath LG,
Samaratunga H, Stahl J, Stapleton AM, Egevad L, Srigley JR, Delahunt B.
Prognostic factors in prostate cancer. Key elements in structured histopathology
reporting of radical prostatectomy specimens. Pathology. 2011 Aug;43(5):410-9.
152.
Josefsson A, Adamo H, Hammarsten P, Granfors T, Stattin P, Egevad L,
Laurent AE, Wikström P, Bergh A. Prostate cancer increases hyaluronan in
surrounding nonmalignant stroma, and this response is associated with tumor
growth and an unfavorable outcome. Am J Pathol. 2011 Oct;179(4):1961-8.
Epub 2011 Aug 18.
153.
Talvitie H, Aström K, Larsson O, Ahlén J, Bergh A, Egevad L. Solitary
fibrous tumor of the prostate: a report of two cases. Pathol Int. 2011
Sep;61(9):536-8. doi: 10.1111/j.1440-1827.2011.02696.x. Epub 2011 Aug 1.
154.
Egevad L. Handling of radical prostatectomy specimens: total or partial
embedding? Histopathology. 2011 Nov;59(5):1011-2; author reply 1012-3.
155.
Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim ST,
Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan
G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Grönberg H, Isaacs WB, Xu
J. Identification of novel CHD1-associated collaborative alterations of genomic
structure and functional assessment of CHD1 in prostate cancer. Oncogene.
2011 Dec 5. [Epub ahead of print]
16
17
156.
Algaba F, Delahunt B, Berney DM, Camparo P, Compérat E, Griffiths D,
Kristiansen G, Lopez-Beltran A, Martignoni G, Moch H, Montironi R, Varma
M, Egevad L. Handling and reporting of nephrectomy specimens for adult renal
tumours: a survey by the European Network of Uropathology. J Clin Pathol.
2012 Feb;65(2):106-13. Epub 2011 Sep 30.
157.
Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim ST,
Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan
G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Grönberg H, Isaacs WB, Xu
J. Identification of novel CHD1-associated collaborative alterations of genomic
structure and functional assessment of CHD1 in prostate cancer. Oncogene.
2011 Dec 5. [Epub ahead of print]
158.
Egevad L. Handling and Reporting of Radical Prostatectomy Specimens
(Diagnostic Histopathology, 2011; 17:428-33)
159.
Kim JW, Kim ST, Turner AR, Young T, Smith S, Liu W, Lindberg J,
Egevad L, Gronberg H, Isaacs WB, Xu J. Identification of new differentially
methylated genes that have potential functional consequences in prostate cancer.
PLoS One. 2012;7(10):e48455.
160.
Hammarsten P, Cipriano M, Josefsson A, Stattin P, Egevad L, Granfors T,
Fowler CJ. Phospho-Akt immunoreactivity in prostate cancer: relationship to
disease severity and outcome, Ki67 and phosphorylated EGFR expression. PLoS
One. 2012;7(10):e47994.
161.
Egevad L. Handling of radical prostatectomy specimens. Histopathology.
2012 Jan;60(1):118-24.
162.
Kharaziha P, Rodriguez P, Li Q, Rundqvist H, Björklund AC, Augsten M,
Ullén A, Egevad L, Wiklund P, Nilsson S, Kroemer G, Grander D, Panaretakis
T. Targeting of distinct signaling cascades and cancer-associated fibroblasts
define the efficacy of Sorafenib against prostate cancer cells. Cell Death Dis.
2012 Jan 26;3:e262.
163.
Egevad L. [The pathologist's role: to diagnose prostatic cancer and
determine prognosis]. Lakartidningen. 2012 Feb 22-28;109(8):403-6
164.
Al-Ubaidi FL, Schultz N, Egevad L, Granfors T, Helleday T. Castration
therapy of prostate cancer results in downregulation of HIF-1alpha levels. Int J
Radiat Oncol Biol Phys. 2012 Mar 1;82(3):1243-8.
165.
Egevad L, Mazzucchelli R, Montironi R. Implications of the International
Society of Urological Pathology modified Gleason grading system. Arch Pathol
Lab Med. 2012 Apr;136(4):426-34
166.
Camparo P, Egevad L, Algaba F, Berney DM, Boccon-Gibod L, Compérat
E, Evans AJ, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran A,
18
Montironi R, Oliveira P, Vainer B, Varma M. Utility of whole slide imaging
and virtual microscopy in prostate pathology. APMIS. 2012 Apr;120(4):298-304
167.
Kristiansen G, Srigley JR, Delahunt B, Egevad L [Diagnostics of radical
prostatectomy specimens. Results of the 2009 consensus conference of the
International Society of Urological Pathology].; Internationalen Gesellschaft für
Urologische Pathologie. Pathologe. 2012 Jul;33(4):337-44
168.
Fine SW, Amin MB, Berney DM, Bjartell A, Egevad L, Epstein JI,
Humphrey PA, Magi-Galluzzi C, Montironi R, Stief C. A Contemporary Update
on Pathology Reporting for Prostate Cancer: Biopsy and Radical Prostatectomy
Specimens. Eur Urol. 2012 Mar 8. [Epub ahead of print]
169.
Josefsson A, Wikström P, Egevad L, Granfors T, Karlberg L, Stattin P,
Bergh A. Low endoglin vascular density and Ki67 index in Gleason score 6
tumours may identify prostate cancer patients suitable for surveillance. Scand J
Urol Nephrol. 2012 Aug;46(4):247-57
170.
Delahunt B, Srigley JR, Montironi R, Egevad L. Urological pathology
comes of age. Pathology. 2012 Aug;44(5):389-90
171.
Liu W, Lindberg J, Sui G, Luo J, Egevad L, Li T, Xie C, Wan M, Kim ST,
Wang Z, Turner AR, Zhang Z, Feng J, Yan Y, Sun J, Bova GS, Ewing CM, Yan
G, Gielzak M, Cramer SD, Vessella RL, Zheng SL, Grönberg H, Isaacs WB, Xu
J. Identification of novel CHD1-associated collaborative alterations of genomic
structure and functional assessment of CHD1 in prostate cancer. Oncogene.
2012 Aug 30;31(35):3939-48
172.
Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A,
Alanen K, Egevad L, Granfors T, Josefsson A, Stattin P, Bergh A, Nevalainen
MT. Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific
death in patients treated by radical prostatectomy. Hum Pathol. 2012 Sep 28.
doi:pii: S0046-8177(12)00207-9. 10.1016/j.humpath.2012.06.001. [Epub ahead
of print]
173.
Ros MM, Bueno-de-Mesquita HB, Kampman E, Aben KK, Büchner FL,
Jansen EH, van Gils CH, Egevad L, Overvad K, Tjønneland A, Roswall N,
Boutron-Ruault MC, Kvaskoff M, Perquier F, Kaaks R, Chang-Claude J,
Weikert S, Boeing H, Trichopoulou A, Lagiou P, Dilis V, Palli D, Pala V,
Sacerdote C, Tumino R, Panico S, Peeters PH, Gram IT, Skeie G, Huerta JM,
Barricarte A, Quirós JR, Sánchez MJ, Buckland G, Larrañaga N, Ehrnström R,
Wallström P, Ljungberg B, Hallmans G, Key TJ, Allen NE, Khaw KT,
Wareham N, Brennan P, Riboli E, Kiemeney LA. Plasma carotenoids and
vitamin C concentrations and risk of urothelial cell carcinoma in the European
Prospective Investigation into Cancer and Nutrition. Am J Clin Nutr. 2012
Oct;96(4):902-10.
174.
Sooriakumaran P, Haendler L, Nyberg T, Gronberg H, Nilsson A,
Carlsson S, Hosseini A, Adding C, Jonsson M, Ploumidis A, Egevad L, Steineck
G, Wiklund P. Biochemical recurrence after robot-assisted radical prostatectomy
19
in a European single-centre cohort with a minimum follow-up time of 5 years.
Eur Urol. 2012 Nov;62(5):768-74
175.
Ros MM, Bueno-de-Mesquita HB, Kampman E, Büchner FL, Aben KK,
Egevad L, Overvad K, Tjønneland A, Roswall N, Clavel-Chapelon F, BoutronRuault MC, Morois S, Kaaks R, Teucher B, Weikert S, von Ruesten A,
Trichopoulou A, Naska A, Benetou V, Saieva C, Pala V, Ricceri F, Tumino R,
Mattiello A, Peeters PH, van Gils CH, Gram IT, Engeset D, Chirlaque MD,
Ardanazx E, Rodríguez L, Amanio P, Gonzalez CA, Sánchez MJ, Ulmert D,
Ernström R, Ljungberg B, Allen NE, Key TJ, Khaw KT, Wareham N, Slimani
N, Romieu I, Kiemeney LA, Riboli E. Fruit and vegetable consumption and risk
of aggressive and non-aggressive urothelial cell carcinomas in the European
Prospective Investigation into Cancer and Nutrition. Eur J Cancer. 2012
Nov;48(17):3267-77
176.
Carlsson S, Bratt O, Stattin P, Egevad L. Current routines for transrectal
ultrasound-guided prostate biopsy: A web-based survey by the Swedish Urology
Network. Scand J Urol Nephrol. 2012 Dec;46(6):405-10
177.
Brimo F, Montironi R, Egevad L, Erbersdobler A, Lin DW, Nelson JB,
Rubin MA, van der Kwast T, Amin M, Epstein JI. Contemporary grading for
prostate cancer: implications for patient care. Eur Urol. 2013 May;63(5):892901.
178.
Lindberg J, Mills IG, Klevebring D, Liu W, Neiman M, Xu J, Wikström
P, Wiklund P, Wiklund F, Egevad L, Grönberg H. The mitochondrial and
autosomal mutation landscapes of prostate cancer. Eur Urol. 2013
Apr;63(4):702-8.
179.
Samaratunga H, Martignoni G, Egevad L, Delahunt B. Premalignant
lesions of the urinary bladder. Pathology. 2013 Apr;45(3):243-50.
180.
Al-Ubaidi FL, Schultz N, Loseva O, Egevad L, Granfors T, Helleday T.
Castration therapy results in decreased ku70 levels in prostate cancer. Clin
Cancer Res. 2013 Mar 15;19(6):1547-56.
181.
Mirtti T, Leiby BE, Abdulghani J, Aaltonen E, Pavela M, Mamtani A,
Alanen K, Egevad L, Granfors T, Josefsson A, Stattin P, Bergh A, Nevalainen
MT. Nuclear Stat5a/b predicts early recurrence and prostate cancer-specific
death in patients treated by radical prostatectomy. Hum Pathol. 2013
Mar;44(3):310-9.
182.
Seipel AH, Wiklund F, Wiklund NP, Egevad L. Histopathological features
of ductal adenocarcinoma of the prostate in 1,051 radical prostatectomy
specimens. Virchows Arch. 2013 Feb 27
183.
Lindberg J, Klevebring D, Liu W, Neiman M, Xu J, Wiklund P, Wiklund
F, Mills IG, Egevad L, Grönberg H. Exome sequencing of prostate cancer
supports the hypothesis of independent tumour origins. Eur Urol. 2013
Feb;63(2):347-53.
20
184.
Varma M, Berney DM, Algaba F, Camparo P, Compérat E, Griffiths DF,
Kristiansen G, Lopez-Beltran A, Montironi R, Egevad L. Prostate needle biopsy
processing: a survey of laboratory practice across Europe. J Clin Pathol. 2013
Feb;66(2):120-3.
185.
Egevad L, Ahmad AS, Algaba F, Berney DM, Boccon-Gibod L, Compérat
E, Evans AJ, Griffiths D, Grobholz R, Kristiansen G, Langner C, Lopez-Beltran
A, Montironi R, Moss S, Oliveira P, Vainer B, Varma M, Camparo P.
Standardization of Gleason grading among 337 European pathologists.
Histopathology. 2013 Jan;62(2):247-56.
186.
Montironi R, Srigley JR, Egevad L, Delahunt B. Recent advances in
urological pathology. Anal Quant Cytol Histol. 2012 Dec;34(6):293-5
187.
Kristiansen A, Wiklund F, Wiklund P, Egevad L. Prognostic significance
of patterns of seminal vesicle invasion in prostate cancer. Histopathology. 2013
Jun;62(7):1049-56
188.
Danneman D, Wiklund F, Wiklund NP, Egevad L. Prognostic
Significance of Histopathological Features of Extra-Prostatic Extension of
Prostate Cancer. Histopathology. 2013 in press